InterAx Biotech Ltd
InterAx Biotech applies machine learning, mathematical modeling, and cellular assays to predict how drug candidates affect cellular signaling and accelerate candidate optimization. The company combines in-house experimental assays with mathematical models and AI in a targeted platform (Deep Signal™) focused on GPCR small molecules to guide lead optimization toward desired cellular responses. InterAx operates as a B2B technology and drug-discovery partner for pharmaceutical and biotech teams, providing platform-driven candidate selection and optimization. Its approach aims to reduce early-stage failure by enabling biology-informed decisions before preclinical trials, and the company advances a portfolio of internally developed and partnered assets to demonstrate platform value.
InterAx Biotech Ltd
InterAx Biotech applies machine learning, mathematical modeling, and cellular assays to predict how drug candidates affect cellular signaling and accelerate candidate optimization. The company combines in-house experimental assays with mathematical models and AI in a targeted platform (Deep Signal™) focused on GPCR small molecules to guide lead optimization toward desired cellular responses. InterAx operates as a B2B technology and drug-discovery partner for pharmaceutical and biotech teams, providing platform-driven candidate selection and optimization. Its approach aims to reduce early-stage failure by enabling biology-informed decisions before preclinical trials, and the company advances a portfolio of internally developed and partnered assets to demonstrate platform value.